# Lincoln Pharmaceuticals (NSE: LINCOLN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/LINCOLN · Pivot · prices to 21 Oct 2026

Lincoln Pharmaceuticals (NSE: LINCOLN) closed at ₹524.30 on 21 Oct 2026. With a market capitalisation of ₹1,068 Cr, it ranks 1435th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 12.2× trailing earnings, against a return on equity of 11.6% in FY26. Over the past year the share price has risen 0.9%. Its 52-week range is ₹440.00 (28 Jan 2026) to ₹770.00 (27 May 2026); the last close is 31.9% below the high. Promoters held 49.78% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹524.30 |
| Market cap | ₹1,068 Cr |
| P/E (trailing) | 12.2 |
| ROE | 11.6% (FY26) |
| ROCE | 15.0% (FY26) |
| Debt to equity | 0.01 |
| 52-week high | ₹770.00 (27 May 2026) |
| 52-week low | ₹440.00 (28 Jan 2026) |
| 1-year return | +0.9% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹623 Cr | ₹82 Cr |
| FY24 | ₹581 Cr | ₹93 Cr |
| FY23 | ₹510 Cr | ₹73 Cr |
| FY22 | ₹472 Cr | ₹69 Cr |
| FY21 | ₹424 Cr | ₹62 Cr |
| FY20 | ₹386 Cr | ₹51 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 49.78%
- Foreign institutions: 4.60%
- Domestic institutions: 0.27%
- Non-institutions: 45.36%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [GPT Healthcare](https://app.pivotnow.in/stock/GPTHEALTH) | ₹139.50 | ₹1,145 Cr | 27.1 | — |
| [Bajaj Healthcare](https://app.pivotnow.in/stock/BAJAJHCARE) | ₹339.90 | ₹1,144 Cr | 50.4 | — |
| [Bafna Pharmaceuticals](https://app.pivotnow.in/stock/BAFNAPH) | ₹470.55 | ₹1,113 Cr | 100.3 | — |
| [Sigachi Industries](https://app.pivotnow.in/stock/SIGACHI) | ₹26.70 | ₹1,020 Cr | — | — |
| [Laxmi Dental](https://app.pivotnow.in/stock/LAXMIDENTL) | ₹182.10 | ₹1,001 Cr | 34.6 | — |
| [Themis Medicare](https://app.pivotnow.in/stock/THEMISMED) | ₹100.30 | ₹924 Cr | — | — |

## Questions and answers

### What is the share price of Lincoln Pharmaceuticals today?

Lincoln Pharmaceuticals (NSE: LINCOLN) last closed at ₹524.30 on 21 Oct 2026. Its 52-week high is ₹770.00 and its 52-week low is ₹440.00.

### What is the market cap of Lincoln Pharmaceuticals?

Lincoln Pharmaceuticals' market capitalisation is ₹1,068 Cr (₹1,068 Cr) at the 19 Oct 2026 close, ranking 1435th among the NSE companies Pivot tracks.

### What is the P/E ratio of Lincoln Pharmaceuticals?

Lincoln Pharmaceuticals trades at a trailing P/E of 12.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 50.4.

### What is the ROE and ROCE of Lincoln Pharmaceuticals?

Return on equity was 11.6% in FY26 and return on capital employed was 15.0% in FY26 (consolidated figures).

### Is Lincoln Pharmaceuticals a debt-free company?

Lincoln Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.

### How has Lincoln Pharmaceuticals stock performed over the last year?

Lincoln Pharmaceuticals' share price has risen 0.9% over the past year, −10.2% over three months and −10.9% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Lincoln Pharmaceuticals?

As of 30 Jun 2026: promoters 49.78%, foreign institutions 4.60%, domestic institutions 0.27%, non-institutions 45.36%.

### Who are Lincoln Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Lincoln Pharmaceuticals by market cap are GPT Healthcare, Bajaj Healthcare, Bafna Pharmaceuticals, Sigachi Industries, Laxmi Dental and Themis Medicare.

### Is Lincoln Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Lincoln Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LINCOLN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.